Year Founded
2002
Ownership
Private
Employees
~50
Therapeutic Areas
OncologyOphthalmologyGastroenterologyImmunologyPulmonology
Stage
Phase 2
Modalities
ImmunoconjugatesAntibody-drug conjugate (ADC)

Iconic Therapeutics General Information

Company has completed Phase 2a EMERGE trial for wet AMD and initiated a second Phase 2 study (DECO) exploring higher dosing regimens. Also has preclinical programs in oncology through partnership with Exelixis.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

ICON-1
Phase 2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Iconic Therapeutics's pipeline data

Book a demo

Key Partnerships

Exelixis, Zymeworks

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Iconic Therapeutics Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Iconic Therapeutics's complete valuation and funding history, request access »

Iconic Therapeutics Investors

Top tier life science investors
Investor Type: Venture Capital
Holding: Minority